The burden of fatigue and quality of life in myeloproliferative disorders (MPDs)
Top Cited Papers
Open Access
- 11 December 2006
- Vol. 109 (1), 68-76
- https://doi.org/10.1002/cncr.22365
Abstract
BACKGROUND. Few objective data exist on the burden of fatigue and other constitutional symptoms in patients with myeloproliferative disorders (MPD). METHODS. The authors used validated instruments of fatigue and physical activity assessment during an Internet‐based symptom survey of 1179 MPD patients (median age, 56 years; 41.4% men). RESULTS. The frequency of self‐reporting was 80.7% for fatigue, which was substantially higher than that of pruritus (52.2%), night sweats (49.2%), bone pain (43.9%), fever (13.7%), and weight loss (13.1%). In the majority of patients, these symptoms restricted participation in both social functions and physical activity. In addition, 34.5% of patients needed assistance with activities of daily living, and 11.2% reported MPD‐associated medical disability. As expected, the presence of myelofibrosis, anemia, splenomegaly, or other features associated with advanced disease favored a higher degree of fatigue. However, fatigue remained the major complaint also in polycythemia vera (84.9%) and essential thrombocythemia (72.4%); these figures were significantly higher than those of published controls (P < .0001). CONCLUSIONS. The current study identifies fatigue as the major contributor to poor quality of life in MPD, provides baseline information on constitutional symptoms, and underscores the need for the incorporation of quality of life assessment in clinical trials. Cancer 2007. © 2006 American Cancer Society.Keywords
This publication has 24 references indexed in Scilit:
- Quality‐of‐life and health benefits of early treatment of mild anemiaCancer, 2006
- The clinical phenotype of wild‐type, heterozygous, and homozygous JAK2V617F in polycythemia veraCancer, 2005
- Hydroxyurea Compared with Anagrelide in High-Risk Essential ThrombocythemiaNew England Journal of Medicine, 2005
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisCancer Cell, 2005
- Quality of life changes following peripheral blood stem cell transplantation and participation in a mixed-type, moderate-intensity, exercise programBone Marrow Transplantation, 2004
- Allogeneic hematopoietic stem cell transplantation for myelofibrosisBlood, 2003
- A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasiaBlood, 2003
- Clinical Factors Associated With Cancer-Related Fatigue in Patients Being Treated for Leukemia and Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2002
- Myelofibrosis with Myeloid MetaplasiaNew England Journal of Medicine, 2000
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987